Trial Profile
A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Caplacizumab (Primary) ; Caplacizumab (Primary) ; Corticosteroids; Cyclophosphamide; Hydroxychloroquine; Mycophenolate mofetil; Rituximab
- Indications Thrombosis; Thrombotic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Acronyms HERCULES
- Sponsors Ablynx
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results of post hoc analysis (from two studies HERCULES and post-HERCULES) assessing the efficacy and safety of caplacizumab in patients with iTTP presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Results from TITAN, HERCULES and other studies, comparing patient-centered outcomes from Germany and Austria, presented at the 63rd American Society of Hematology Annual Meeting and Exposition